Rocha, Clarissa Ribeiro Reily; Kajitani, Gustavo Satoru; Quinet, Annabel; Fortunato, Rodrigo Soares; Menck, Carlos Frederico Martins 
Source: Oncotarget. Unidade: ICB
Subjects: GLIOMA, MELANOMA, NEOPLASIAS, FÁRMACOS, TERAPÊUTICA, DNA, ESTRESSE OXIDATIVO, MICROBIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Clarissa Ribeiro Reily et al. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget, v. 7, n. 30, p. 48081-48092, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10129. Acesso em: 06 nov. 2024.APA
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016). NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget, 7( 30), 48081-48092. doi:10.18632/oncotarget.10129NLM
Rocha CRR, Kajitani GS, Quinet A, Fortunato RS, Menck CFM. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells [Internet]. Oncotarget. 2016 ; 7( 30): 48081-48092.[citado 2024 nov. 06 ] Available from: https://doi.org/10.18632/oncotarget.10129Vancouver
Rocha CRR, Kajitani GS, Quinet A, Fortunato RS, Menck CFM. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells [Internet]. Oncotarget. 2016 ; 7( 30): 48081-48092.[citado 2024 nov. 06 ] Available from: https://doi.org/10.18632/oncotarget.10129
